

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.	)	Examiner: Jennifer M. Kim
	)	
Serial No: 09/450,609	)	Art Unit: 1617
	)	
Filed: November 30, 1999	)	Deposit Account No: 04-1403
	)	
Confirmation No: 7926	)	Customer No: 22827
	)	
Title: New Pharmaceutical Composition and the	)	
Process for Its Preparation	)	

**AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is a response/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is to be treated as the signature to the attachment in absence of a signature thereto.

Fee requirements (if any) have been calculated as shown below:

	Claims remaining after amendment		Highest number previously paid for		Present Extra		Additional Fee
Total Effective Claims	15	minus	20	=		X \$ 50 =	\$ <u>0.00</u>
Independent Claims	2	minus	3	=		X \$210 =	\$ <u>0.00</u>

If amendment enters proper multiple dependent claim(s) into this application  
for first time, add \$370.00 (per application) \$ 0.00

Since Official Action set an original due date of January 18, 2008,  
**PETITION** is hereby made for an extension to cover the date this  
response is filed for which the requisite fee is enclosed (1 month \$120;  
2 months \$460; 3 months \$1,050; 4 months \$1,640, 5 months \$2,230 \$ 460.00

If Terminal Disclaimer enclosed, add Rule 20(d) Official Fee (\$130.00) \$ 0.00

Other: RCE \$ 810.00

**SUBTOTAL:** \$ 1,270.00

If "small entity" verified statement filed ☐ previously,  
☐ herewith, enter one-half (½) of subtotal and subtract - \$ 0.00

---

The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any fees in addition to the fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (deficiency only) now or hereafter relative to this application and the resulting official document under Rule 20, or credit any overpayment, to our Account No. shown in the heading hereof. This statement does not authorize charge of the issue fee in this case.

**DORITY & MANNING ATTORNEYS AT LAW, P.A.**

ADDRESS:

Post Office Box 1449  
Greenville, SC 29602 USA  
Customer ID No.: 22827  
Telephone: (864) 271-1592  
Facsimile: (864) 233-7342

By: Jason W. Johnston Reg. No: 45,675

Signature: 

Date: March 17, 2008

---

I hereby certify that this correspondence and all attachments and any fee(s) are being electronically transmitted via the internet to the U.S. Patent and Trademark Office using the Electronic Patent Filing System on March 17, 2008.

Sandra S. Perkins

(Typed or printed name of person transmitting documents)



(Signature of person transmitting documents)

**PATENT**

**ATTORNEY DOCKET NO: RED-1 (DRF 3.0-051)**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application: Weibel, et al.	)	Examiner: Jennifer Kim
	)	
Serial No: 09/450,609	)	Art Unit: 1617
	)	
Filed: November 30, 1999	)	Deposit Account No: 04-1403
	)	
Confirmation No: 7926	)	Customer No: 22827
	)	
Title: New Pharmaceutical Composition)	)	
and the Process for Its	)	
Preparation	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Dear Sir:

In response to the Office Action dated October 18, 2007 and in conjunction with the Request for Continued Examination ("RCE") submitted herewith, please amend the above-captioned application as follows:

**Amendment to the Claims** are reflected in the listing of claims beginning on pg. 2 of this paper.

**Remarks** begin on pg. 5 of this paper.